Calcyphosine Antikörper (AA 101-189) (AbBy Fluor® 350)

Produktnummer ABIN1395513

Produktdetails anti-Calcyphosine Antikörper (AbBy Fluor® 350)

Target: Calcyphosine (CAPS)

Bindungsspezifität: AA 101-189

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Calcyphosine Antikörper ist konjugiert mit AbBy Fluor® 350

Applikation: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Kreuzreaktivität: Human

Homologie: Dog,Cow,Sheep,Pig,Rabbit

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human Calcyphosine 1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu Calcyphosine

Target: Calcyphosine (CAPS)

Andere Bezeichnung: Calcyphosine 1/CAPS1 (CAPS Produkte)

Synonyme: CAPS1 antikoerper, Caps antikoerper, Caps1 antikoerper, Caps2 antikoerper, caps1 antikoerper, MGC84373 antikoerper, CAPS antikoerper, calcyphosine antikoerper, calcium dependent secretion activator antikoerper, calcyphosine S homeolog antikoerper, CAPS antikoerper, Cadps antikoerper, caps.S antikoerper, caps antikoerper, Caps antikoerper

Hintergrund:

Synonyms: Calcyphosin, Calcyphosine 1, Calcyphosine, CAPS, CAPS1, CAYP1_HUMAN, Thyroid protein p24.

Background: CAPS1 is a 189 amino acid cytoplasmic protein that contains four EF-hand domains, which serve as calcium-binding sites, and was first identified in canine thyroid. Interestingly, CAPS1 is much less abundant in humans than in canines. Synthesis and phosphorylation of CAPS1 is upregulated by cAMP-agonists in thyrocytes. CAPS1 likely functions in the regulation of ionic transport and may be involved in cross-signaling between cAMP and Ca(+2)-phophatidylinositol cascades. In addition to thyriod, CAPS1 is expressed in brain, salivary glands and lung. Expression of CAPS1 is increased in endometrial cancer and prognosis seems to be dependent on the level of CAPS1 expression, indicating that CAPS1 may be an appropriate prognostic marker for patient survival.